Safe Use of Subcutaneous Diphenhydramine in the Inpatient Hospice Unit

Background: Diphenhydramine (DPH) is most commonly used via oral, topical, intramuscular (IM) and intravenous (IV) routes for the palliation of pruritus, treatment of extrapyramidal symptoms, management of parkinsonism and for allergic reactions. However, many hospice patients are unable to take ora...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of hospice & palliative medicine 2017-12, Vol.34 (10), p.954-957
Hauptverfasser: Chen, Aileen, Loquias, Erwin J., Roshan, Ramesh, Levene, Richard, Zelhof, Raymond, Hickey, Terry, Cooney, Gail Austin, Gonzalez, Faustino
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 957
container_issue 10
container_start_page 954
container_title American journal of hospice & palliative medicine
container_volume 34
creator Chen, Aileen
Loquias, Erwin J.
Roshan, Ramesh
Levene, Richard
Zelhof, Raymond
Hickey, Terry
Cooney, Gail Austin
Gonzalez, Faustino
description Background: Diphenhydramine (DPH) is most commonly used via oral, topical, intramuscular (IM) and intravenous (IV) routes for the palliation of pruritus, treatment of extrapyramidal symptoms, management of parkinsonism and for allergic reactions. However, many hospice patients are unable to take oral medications and/or do not have IV access. Moreover, topical administration has a relatively slow rate of absorption. For this reason, in the hospice setting it is not uncommon for diphenhydramine to be administered via the subcutaneous (SC) route secondary to its ease of access, low infection rates and its low levels of discomfort. In contrast, outside the hospice setting, subcutaneous DPH has not been widely used, primarily because of a handful of case reports published in the 1990’s that report skin necrosis following subcutaneous administration of DPH for local anesthesia. Since these early case reports, however, there has been very little in the way of research to examine this further. The aim of this study is to provide objective data concerning the safe use of subcutaneous diphenhydramine, as part of our efforts to improve upon safe practices in our organization. Methods: This is a retrospective review of records from 6 of our inpatient hospice units obtained from our pharmacy database for patients who received at least one subcutaneous injection of diphenhydramine between 2012-2015. Selected patients were then subsequently screened for post-administration skin necrosis, as recorded in our quality assurance database during the same time period. Results: A total of 648 diphenhydramine subcutaneous injections were administered in109 individual patients. None of the patients were reported to have an adverse cutaneous reaction. Conclusions: This retrospective review demonstrates that subcutaneous diphenhydramine injection is a safe alternative to oral and other parenteral routes, and may be particularly valuable in terminally ill patients, who are often unable to swallow and are without IV access.
doi_str_mv 10.1177/1049909116668160
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1859720299</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1049909116668160</sage_id><sourcerecordid>1859720299</sourcerecordid><originalsourceid>FETCH-LOGICAL-c337t-166d7fc64a7621bdc1a4b55ea289f1971711165e15c0284d8d389f77c3a71ce63</originalsourceid><addsrcrecordid>eNp1UD1PwzAUtBCIlsLOhDKyBPzsOI5HVCitVImhdI4c54W6apwQJ0P_Pa4CDEhM70n3obsj5BboA4CUj0ATpagCSNM0g5SekSkonsVMgjgPf4DjEz4hV97vKeUsSeCSTJhMmeAimZLFRlcYbT1GTRVthsIMvXbYDD56tu0O3e5Ydrq2DiPron6H0cq1urfo-mjZ-NaaIHa2vyYXlT54vPm-M7JdvLzPl_H67XU1f1rHhnPZxyFnKSuTJjoEgKI0oJNCCNQsUxUoCRJCF4EgDGVZUmYlD4CUhmsJBlM-I_ejb9s1nwP6Pq-tN3g4jKFzyISSjDKlApWOVNM13ndY5W1na90dc6D5ab3873pBcvftPhQ1lr-Cn7kCIR4JXn9gvm-GzoW2_xt-AWjcdW8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1859720299</pqid></control><display><type>article</type><title>Safe Use of Subcutaneous Diphenhydramine in the Inpatient Hospice Unit</title><source>SAGE Complete A-Z List</source><source>MEDLINE</source><creator>Chen, Aileen ; Loquias, Erwin J. ; Roshan, Ramesh ; Levene, Richard ; Zelhof, Raymond ; Hickey, Terry ; Cooney, Gail Austin ; Gonzalez, Faustino</creator><creatorcontrib>Chen, Aileen ; Loquias, Erwin J. ; Roshan, Ramesh ; Levene, Richard ; Zelhof, Raymond ; Hickey, Terry ; Cooney, Gail Austin ; Gonzalez, Faustino</creatorcontrib><description>Background: Diphenhydramine (DPH) is most commonly used via oral, topical, intramuscular (IM) and intravenous (IV) routes for the palliation of pruritus, treatment of extrapyramidal symptoms, management of parkinsonism and for allergic reactions. However, many hospice patients are unable to take oral medications and/or do not have IV access. Moreover, topical administration has a relatively slow rate of absorption. For this reason, in the hospice setting it is not uncommon for diphenhydramine to be administered via the subcutaneous (SC) route secondary to its ease of access, low infection rates and its low levels of discomfort. In contrast, outside the hospice setting, subcutaneous DPH has not been widely used, primarily because of a handful of case reports published in the 1990’s that report skin necrosis following subcutaneous administration of DPH for local anesthesia. Since these early case reports, however, there has been very little in the way of research to examine this further. The aim of this study is to provide objective data concerning the safe use of subcutaneous diphenhydramine, as part of our efforts to improve upon safe practices in our organization. Methods: This is a retrospective review of records from 6 of our inpatient hospice units obtained from our pharmacy database for patients who received at least one subcutaneous injection of diphenhydramine between 2012-2015. Selected patients were then subsequently screened for post-administration skin necrosis, as recorded in our quality assurance database during the same time period. Results: A total of 648 diphenhydramine subcutaneous injections were administered in109 individual patients. None of the patients were reported to have an adverse cutaneous reaction. Conclusions: This retrospective review demonstrates that subcutaneous diphenhydramine injection is a safe alternative to oral and other parenteral routes, and may be particularly valuable in terminally ill patients, who are often unable to swallow and are without IV access.</description><identifier>ISSN: 1049-9091</identifier><identifier>EISSN: 1938-2715</identifier><identifier>DOI: 10.1177/1049909116668160</identifier><identifier>PMID: 27625354</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Basal Ganglia Diseases - drug therapy ; Diphenhydramine - administration &amp; dosage ; Diphenhydramine - adverse effects ; Diphenhydramine - therapeutic use ; Female ; Hospices - methods ; Humans ; Injections, Subcutaneous ; Male ; Middle Aged ; Necrosis - chemically induced ; Nursing ; Pruritus - drug therapy ; Retrospective Studies ; Skin - pathology</subject><ispartof>American journal of hospice &amp; palliative medicine, 2017-12, Vol.34 (10), p.954-957</ispartof><rights>The Author(s) 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c337t-166d7fc64a7621bdc1a4b55ea289f1971711165e15c0284d8d389f77c3a71ce63</citedby><cites>FETCH-LOGICAL-c337t-166d7fc64a7621bdc1a4b55ea289f1971711165e15c0284d8d389f77c3a71ce63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1049909116668160$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1049909116668160$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27625354$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Aileen</creatorcontrib><creatorcontrib>Loquias, Erwin J.</creatorcontrib><creatorcontrib>Roshan, Ramesh</creatorcontrib><creatorcontrib>Levene, Richard</creatorcontrib><creatorcontrib>Zelhof, Raymond</creatorcontrib><creatorcontrib>Hickey, Terry</creatorcontrib><creatorcontrib>Cooney, Gail Austin</creatorcontrib><creatorcontrib>Gonzalez, Faustino</creatorcontrib><title>Safe Use of Subcutaneous Diphenhydramine in the Inpatient Hospice Unit</title><title>American journal of hospice &amp; palliative medicine</title><addtitle>Am J Hosp Palliat Care</addtitle><description>Background: Diphenhydramine (DPH) is most commonly used via oral, topical, intramuscular (IM) and intravenous (IV) routes for the palliation of pruritus, treatment of extrapyramidal symptoms, management of parkinsonism and for allergic reactions. However, many hospice patients are unable to take oral medications and/or do not have IV access. Moreover, topical administration has a relatively slow rate of absorption. For this reason, in the hospice setting it is not uncommon for diphenhydramine to be administered via the subcutaneous (SC) route secondary to its ease of access, low infection rates and its low levels of discomfort. In contrast, outside the hospice setting, subcutaneous DPH has not been widely used, primarily because of a handful of case reports published in the 1990’s that report skin necrosis following subcutaneous administration of DPH for local anesthesia. Since these early case reports, however, there has been very little in the way of research to examine this further. The aim of this study is to provide objective data concerning the safe use of subcutaneous diphenhydramine, as part of our efforts to improve upon safe practices in our organization. Methods: This is a retrospective review of records from 6 of our inpatient hospice units obtained from our pharmacy database for patients who received at least one subcutaneous injection of diphenhydramine between 2012-2015. Selected patients were then subsequently screened for post-administration skin necrosis, as recorded in our quality assurance database during the same time period. Results: A total of 648 diphenhydramine subcutaneous injections were administered in109 individual patients. None of the patients were reported to have an adverse cutaneous reaction. Conclusions: This retrospective review demonstrates that subcutaneous diphenhydramine injection is a safe alternative to oral and other parenteral routes, and may be particularly valuable in terminally ill patients, who are often unable to swallow and are without IV access.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Basal Ganglia Diseases - drug therapy</subject><subject>Diphenhydramine - administration &amp; dosage</subject><subject>Diphenhydramine - adverse effects</subject><subject>Diphenhydramine - therapeutic use</subject><subject>Female</subject><subject>Hospices - methods</subject><subject>Humans</subject><subject>Injections, Subcutaneous</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Necrosis - chemically induced</subject><subject>Nursing</subject><subject>Pruritus - drug therapy</subject><subject>Retrospective Studies</subject><subject>Skin - pathology</subject><issn>1049-9091</issn><issn>1938-2715</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1UD1PwzAUtBCIlsLOhDKyBPzsOI5HVCitVImhdI4c54W6apwQJ0P_Pa4CDEhM70n3obsj5BboA4CUj0ATpagCSNM0g5SekSkonsVMgjgPf4DjEz4hV97vKeUsSeCSTJhMmeAimZLFRlcYbT1GTRVthsIMvXbYDD56tu0O3e5Ydrq2DiPron6H0cq1urfo-mjZ-NaaIHa2vyYXlT54vPm-M7JdvLzPl_H67XU1f1rHhnPZxyFnKSuTJjoEgKI0oJNCCNQsUxUoCRJCF4EgDGVZUmYlD4CUhmsJBlM-I_ejb9s1nwP6Pq-tN3g4jKFzyISSjDKlApWOVNM13ndY5W1na90dc6D5ab3873pBcvftPhQ1lr-Cn7kCIR4JXn9gvm-GzoW2_xt-AWjcdW8</recordid><startdate>201712</startdate><enddate>201712</enddate><creator>Chen, Aileen</creator><creator>Loquias, Erwin J.</creator><creator>Roshan, Ramesh</creator><creator>Levene, Richard</creator><creator>Zelhof, Raymond</creator><creator>Hickey, Terry</creator><creator>Cooney, Gail Austin</creator><creator>Gonzalez, Faustino</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201712</creationdate><title>Safe Use of Subcutaneous Diphenhydramine in the Inpatient Hospice Unit</title><author>Chen, Aileen ; Loquias, Erwin J. ; Roshan, Ramesh ; Levene, Richard ; Zelhof, Raymond ; Hickey, Terry ; Cooney, Gail Austin ; Gonzalez, Faustino</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c337t-166d7fc64a7621bdc1a4b55ea289f1971711165e15c0284d8d389f77c3a71ce63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Basal Ganglia Diseases - drug therapy</topic><topic>Diphenhydramine - administration &amp; dosage</topic><topic>Diphenhydramine - adverse effects</topic><topic>Diphenhydramine - therapeutic use</topic><topic>Female</topic><topic>Hospices - methods</topic><topic>Humans</topic><topic>Injections, Subcutaneous</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Necrosis - chemically induced</topic><topic>Nursing</topic><topic>Pruritus - drug therapy</topic><topic>Retrospective Studies</topic><topic>Skin - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Aileen</creatorcontrib><creatorcontrib>Loquias, Erwin J.</creatorcontrib><creatorcontrib>Roshan, Ramesh</creatorcontrib><creatorcontrib>Levene, Richard</creatorcontrib><creatorcontrib>Zelhof, Raymond</creatorcontrib><creatorcontrib>Hickey, Terry</creatorcontrib><creatorcontrib>Cooney, Gail Austin</creatorcontrib><creatorcontrib>Gonzalez, Faustino</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of hospice &amp; palliative medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Aileen</au><au>Loquias, Erwin J.</au><au>Roshan, Ramesh</au><au>Levene, Richard</au><au>Zelhof, Raymond</au><au>Hickey, Terry</au><au>Cooney, Gail Austin</au><au>Gonzalez, Faustino</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safe Use of Subcutaneous Diphenhydramine in the Inpatient Hospice Unit</atitle><jtitle>American journal of hospice &amp; palliative medicine</jtitle><addtitle>Am J Hosp Palliat Care</addtitle><date>2017-12</date><risdate>2017</risdate><volume>34</volume><issue>10</issue><spage>954</spage><epage>957</epage><pages>954-957</pages><issn>1049-9091</issn><eissn>1938-2715</eissn><abstract>Background: Diphenhydramine (DPH) is most commonly used via oral, topical, intramuscular (IM) and intravenous (IV) routes for the palliation of pruritus, treatment of extrapyramidal symptoms, management of parkinsonism and for allergic reactions. However, many hospice patients are unable to take oral medications and/or do not have IV access. Moreover, topical administration has a relatively slow rate of absorption. For this reason, in the hospice setting it is not uncommon for diphenhydramine to be administered via the subcutaneous (SC) route secondary to its ease of access, low infection rates and its low levels of discomfort. In contrast, outside the hospice setting, subcutaneous DPH has not been widely used, primarily because of a handful of case reports published in the 1990’s that report skin necrosis following subcutaneous administration of DPH for local anesthesia. Since these early case reports, however, there has been very little in the way of research to examine this further. The aim of this study is to provide objective data concerning the safe use of subcutaneous diphenhydramine, as part of our efforts to improve upon safe practices in our organization. Methods: This is a retrospective review of records from 6 of our inpatient hospice units obtained from our pharmacy database for patients who received at least one subcutaneous injection of diphenhydramine between 2012-2015. Selected patients were then subsequently screened for post-administration skin necrosis, as recorded in our quality assurance database during the same time period. Results: A total of 648 diphenhydramine subcutaneous injections were administered in109 individual patients. None of the patients were reported to have an adverse cutaneous reaction. Conclusions: This retrospective review demonstrates that subcutaneous diphenhydramine injection is a safe alternative to oral and other parenteral routes, and may be particularly valuable in terminally ill patients, who are often unable to swallow and are without IV access.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>27625354</pmid><doi>10.1177/1049909116668160</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1049-9091
ispartof American journal of hospice & palliative medicine, 2017-12, Vol.34 (10), p.954-957
issn 1049-9091
1938-2715
language eng
recordid cdi_proquest_miscellaneous_1859720299
source SAGE Complete A-Z List; MEDLINE
subjects Adult
Aged
Aged, 80 and over
Basal Ganglia Diseases - drug therapy
Diphenhydramine - administration & dosage
Diphenhydramine - adverse effects
Diphenhydramine - therapeutic use
Female
Hospices - methods
Humans
Injections, Subcutaneous
Male
Middle Aged
Necrosis - chemically induced
Nursing
Pruritus - drug therapy
Retrospective Studies
Skin - pathology
title Safe Use of Subcutaneous Diphenhydramine in the Inpatient Hospice Unit
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T03%3A27%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safe%20Use%20of%20Subcutaneous%20Diphenhydramine%20in%20the%20Inpatient%20Hospice%20Unit&rft.jtitle=American%20journal%20of%20hospice%20&%20palliative%20medicine&rft.au=Chen,%20Aileen&rft.date=2017-12&rft.volume=34&rft.issue=10&rft.spage=954&rft.epage=957&rft.pages=954-957&rft.issn=1049-9091&rft.eissn=1938-2715&rft_id=info:doi/10.1177/1049909116668160&rft_dat=%3Cproquest_cross%3E1859720299%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1859720299&rft_id=info:pmid/27625354&rft_sage_id=10.1177_1049909116668160&rfr_iscdi=true